Hoth Therapeutics, Inc. (NASDAQ:HOTH) on Thursday shared interim results from the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 trial evaluating HT-001 in cancer patients receiving EGFR inhibitor therapy.
Hoth Therapeutics is trading with a session volume of 2.199 million compared to the average volume of 397.07 thousand. 52-week stock range falls between $0.6554 and $2.115, according to Benzinga Pro data.
Data
In the open-label PK cohort, 100% of evaluable patients achieved clinical response by Week 6, accompanied by an approximate 50% reduction in investigator-assessed disease severity (using the ARIGA scale) from baseline.
All evaluable patients reached ARIGA ≤1 by Week 6, placing the entire evaluable cohort within the low-severity disease range.
Improvements were observed as early as Week 3 and were maintained through Week 6, demonstrating both rapid onset and durability of response.
In addition to the primary endpoint, supportive clinical endpoints showed meaningful improvements, including a ~34% improvement in oncology toxicity (CTCAE) and a ~37% reduction in patient-reported pruritus, highlighting a broad and consistent treatment effect across multiple clinically relevant measures.
In September 2025, Benzinga exclusively reported Hoth Therapeutics’ combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT.
HT-KIT triggered significant tumor cell death in preclinical models of gastrointestinal stromal tumors (GIST) and systemic mastocytosis as early as 24 hours post-treatment, with statistically significant tumor shrinkage observed by day 8.
HOTH Exhibits Bearish Short-Term Trend
The stock is currently trading 2.7% below its 20-day simple moving average (SMA) and 3.5% below its 50-day SMA, indicating a bearish trend in the short term. Over the past 12 months, shares have decreased approximately 22.79% and are positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the company.
The RSI is at 45.29, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is above its signal line, indicating bullish momentum in the short term.
The combination of neutral RSI and bullish MACD suggests mixed momentum for Hoth Therapeutics.
- Key Resistance: $1.05
- Key Support: $1.00
Analyst Consensus & Recent Actions:
The stock carries a Buy Rating with an average price target of $6.50. Recent analyst moves include:
- D. Boral Capital: Buy (Maintains Target to $5.00) (Dec. 4, 2025)
HOTH Price Action: Hoth Therapeutics stock is up 2.86% at $1.075 at the last check on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments